Formulation: A 1 mg/ml solution in methanol
Pricing updated 2018-02-25. Prices are subject to change without notice.
Morphine (CRM) (Item No. ISO60147) is a certified reference material that is structurally categorized as an opioid. It is a natural phenanthrene that is commonly used to suppress pain through its selective action at the µ opioid receptor.1,2 Undesirable effects of morphine include addiction potential, respiratory depression, constipation, and development of tolerance.3,4 This product is intended for research and forensic applications.
Cayman Chemical products containing Certified Reference Material (CRM) in the name are highly qualified materials manufactured and tested to meet ISO/IEC 17025 and ISO Guide 34 international guidelines for reference materials. These materials are tested using validated analytical methods on qualified instrumentation to ensure traceability to SI units of measure. Cayman’s CRMs are tested for Homogeneity and Stability and are provided with a certificate stating the CRM property value(s) along with the combined uncertainty of the property value(s). These materials are intended for quantitative applications where quantitative accuracy and uncertainty are critical. Cayman Chemical is committed to providing quality products to its customers as evidenced by its accreditation to the ISO/IEC 17025 and ISO Guide 34 standards. All traceable CRMs may be distinguished by their CofAs and can be downloaded below using the batch number located on the product label. For a representative CofA please contact our technical support.
Warning - this product is not for human or veterinary use.
View our Base Peak Identification Tool
View our Flipbook Identification Tool
View the Cayman Structure Database for chemical structure definitions for many Cayman products
View the Cayman Spectral Library (CSL) for ChemStation-searchable GC-MS spectra of many of Cayman's emerging forensic drug standards
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Chartoff, E.H. and Mavrikaki, M. Sex differences in kappa opioid receptor function and their potential impact on addiction. Front.Neurosci. 9:466, (2015).
2. Trescot, A.M.,Datta, S.,Lee, M., et al. Opioid pharmacology. Pain Physician 11, S133-S153 (2008).
3. Ananthan, S. Opioid ligands with mixed μ/δ opioid receptor interactions: An emerging approach to novel analgesics. AAPS J. 8(1), E118-125 (2006).
4. Le Merrer, J.,Becker, J.A.J.,Befort, K., et al. Reward processing by the opioid system in the brain. Physiol.Rev. 89(4), 1379-1412 (2009).